AstraZeneca Seeks To Ward Off Brilinta Patent Infringer In India
Executive Summary
An Indian court has blocked an alleged infringer of AstraZeneca's patent pertaining to Brilinta (ticagrelor), but the case, some experts claim, also brings to the fore certain controversial tactics at play in the legal arena as large firms pursue litigation to safeguard their intellectual property.
You may also be interested in...
AZ's Brilinta Patents 'Vulnerable' To Challenge In India
An Indian court has lifted restraining orders against Micro Labs, Dr Reddy’s and Natco and held that they have made a “strong credible challenge” to the validity of AstraZeneca’s patents for Brilinta in the country. The UK firm has appealed the order.
AstraZeneca Bolstering India Play With $90m Investment Plan
AstraZeneca expects to invest $90m over five years to shore up its footprint in India – a market where the Anglo-Swedish major has introduced a string of new products but has also had a fair share of challenges.
Legal Wrangles: Foreign Firms Gaming The System In India?
Indian companies have cried foul over what they claim are "unethical" practices deployed by foreign firms in the legal arena, among others, to safeguard their "patent monopoly".